Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arturo Soto-Matos

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Chemotherapy|August 30, 2014
Experience with trabectedin in an advanced sarcoma patient on peritoneal dialysis for end-stage renal failureMaung Maung Myat Moe, Carlos Fernandez Teruel, Arturo Soto-Matos
Cancer Chemotherapy and Pharmacology|June 22, 2015
Population pharmacokinetics of kahalalide F in advanced cancer patientsBernardo Miguel-Lillo, Belén Valenzuela, José Esteban Peris-Ribera, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2008
Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjectsRicardo Nalda-Molina, Belén Valenzuela, Amelia Ramon-Lopez, et al.
Investigational New Drugs|July 13, 2010
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomasRamón Salazar, Ruth Plummer, Ana Oaknin, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2011
Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patientsCarlos Pérez-Ruixo, Belén Valenzuela, Carlos Fernández Teruel, et al.
Clinical Pharmacokinetics|October 12, 2012
Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®))Mario González-Sales, Belén Valenzuela, Carlos Pérez-Ruixo, et al.
Clinical Pharmacokinetics|September 15, 2007
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patientsJuan Jose Perez-Ruixo, Peter Zannikos, Sarapee Hirankarn, et al.
Cancer Chemotherapy and Pharmacology|March 19, 2011
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysisClaudia Lebedinsky, Javier Gómez, Youn C Park, et al.
Marine Drugs|July 13, 2011
Plitidepsin has a safe cardiac profile: a comprehensive analysisArturo Soto-Matos, Sergio Szyldergemajn, Sonia Extremera, et al.
Cancer Chemotherapy and Pharmacology|October 9, 2007
Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatmentGerald J Fetterly, Joel S Owen, Kim Stuyckens, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Chemotherapy|August 30, 2014
Experience with trabectedin in an advanced sarcoma patient on peritoneal dialysis for end-stage renal failureMaung Maung Myat Moe, Carlos Fernandez Teruel, Arturo Soto-Matos
Cancer Chemotherapy and Pharmacology|June 22, 2015
Population pharmacokinetics of kahalalide F in advanced cancer patientsBernardo Miguel-Lillo, Belén Valenzuela, José Esteban Peris-Ribera, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2008
Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjectsRicardo Nalda-Molina, Belén Valenzuela, Amelia Ramon-Lopez, et al.
Investigational New Drugs|July 13, 2010
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomasRamón Salazar, Ruth Plummer, Ana Oaknin, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2011
Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patientsCarlos Pérez-Ruixo, Belén Valenzuela, Carlos Fernández Teruel, et al.
Clinical Pharmacokinetics|October 12, 2012
Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®))Mario González-Sales, Belén Valenzuela, Carlos Pérez-Ruixo, et al.
Clinical Pharmacokinetics|September 15, 2007
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patientsJuan Jose Perez-Ruixo, Peter Zannikos, Sarapee Hirankarn, et al.
Cancer Chemotherapy and Pharmacology|March 19, 2011
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysisClaudia Lebedinsky, Javier Gómez, Youn C Park, et al.
Marine Drugs|July 13, 2011
Plitidepsin has a safe cardiac profile: a comprehensive analysisArturo Soto-Matos, Sergio Szyldergemajn, Sonia Extremera, et al.
Cancer Chemotherapy and Pharmacology|October 9, 2007
Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatmentGerald J Fetterly, Joel S Owen, Kim Stuyckens, et al.
Pageof 2